



1647

PATENT
Attorney Docket No.: JHU1690-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wong et al. Art Unit: 1647
Application No.: 09/708,096 Examiner: C.J. Nichols
Filed: November 3, 2000
Title: METHOD OF USING AN ANTI-BACE1 ANTIBODY TO INHIBIT
BACE1 MEDIATED A β 11-40/42 PEPTIDE PRODUCTION
(Amended)

Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application please find:

1. Amendment in Response to the Office Action mailed October 11, 2002, including Exhibit A, (9 pages); and
2. Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, **January 10, 2003**, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.

Carrie E. Bickle
(Name of Person Mailing Paper)

Carrie E. Bickle
(Signature)

January 10, 2003
(Date)

In the Application of:

Wong et al.

Application No.: 09/708,096

Filed: November 3, 2000

Page 2


PATENT

Attorney Docket No. JHU1800-1

No fee is deemed necessary in connection with the filing of this paper. However, if a fee is required, the Commissioner is hereby authorized to charge any additional required fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 50-1355. A duplicate copy of this sheet is attached.

Respectfully submitted,

Date: January 10, 2003



Lisa A Haile, J.D., Ph.D.

Reg. No. 38,347

Telephone: (858) 677-1456

Facsimile: (858) 677-1465

USPTO Customer Number 28213
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133



PATENT
ATTORNEY DOCKET No.: JHU1690-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wong et al. Art Unit: 1647
Application No.: 09/708,096 Examiner: C.J. Nichols
Filed: November 3, 2000
Title: METHOD OF USING AN ANTI-BACE1 ANTIBODY TO INHIBIT
BACE1 MEDIATED A β 11-40/42 PEPTIDE PRODUCTION
(Amended)


Commissioner for Patents
Washington, D.C. 20231

AMENDMENT IN RESPONSE TO THE OFFICE ACTION

Sir:

Responsive to the Office Action mailed October 11, 2002 (Paper No. 8), entry of the amendments and reconsideration of the application in view thereof and of the following remarks are respectively requested.

RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, January 10, 2003 , in an envelope addressed to: Commissioner for Patents, Washington, DC 20231.	
Carrie E. Bickle (Name of Person Mailing Paper)	
 (Signature)	January 10, 2003 (Date)

I. AMENDMENTS

A. Title

Please delete the original Title and substitute therefor:

--METHOD OF USING AN ANTI-BACE1 ANTIBODY TO INHIBIT BACE1
MEDIATED A β 11-40/42 PEPTIDE PRODUCTION--

B. In the Specification

At page 1, please amend the paragraph at lines 6-8 to read as follows:

This application claims priority under 35 U.S.C. §119(e)(1) from Provisional Application Serial No. 60/244,051, filed October 27, 2000, entitled "Beta-Secretase (BACE1) Knockout Mice".

Please amend the paragraph bridging pages 44 to 45 of the application to read as follows:

The positive selectable marker encodes a selectable marker which affords a means for selecting cells which have integrated targeting transgene sequences. The negative selectable marker encodes a selectable marker which affords a means for selecting cells which do not have an integrated copy of the negative selection expression cassette. Thus, by a combination positive-negative selection protocol, it is possible to select cells that have undergone homologous replacement recombination and incorporated the portion of the transgene between the homology regions (*i.e.*, the replacement region) into a chromosomal location by selecting for the presence of the positive marker and for the absence of the negative marker. Preferred selectable markers for inclusion in the targeting constructs of the invention encode and express a selectable drug resistance marker and/or a HSV thymidine kinase enzyme. Suitable drug resistance genes include, for example: gpt (xanthine-guanine phosphoribosyltransferase), which can be selected for with mycophenolic acid; neo (neomycin phosphotransferase), which can be selected for with G418 or hygromycin; and DFHR (dihydrofolate reductase), which can be selected for with methotrexate (Mulligan and Berg (1981) Proc. Natl. Acad. Sci. (U.S.A.) 78: 2072; Southern and Berg (1982) J. Mol. Appl. Genet. 1: 327; which are incorporated herein by reference).